Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.43 |
| ▸ | ITGAV | P06756 | 14/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811498 | 0.91 | ITGB3 (0.40) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7744338 | 0.90 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL14585806 | 0.89 | MC4R (0.44) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7746130 | 0.89 | MC4R (0.44) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7743862 | 0.89 | MC4R (0.44) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7746015 | 0.89 | MC4R (0.44) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7746278 | 0.88 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7738610 | 0.87 | ITGB3 (0.40) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7744204 | 0.85 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL14585787 | 0.84 | ITGB3 (0.41) | ITGB3ITGAVITGA2BITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818659-B2 | TARGETS AND BINDS BIOLOGICAL RECEPTORS; MEDICAL DIAGNOSIS; MAGNETIC RESONANCE, X-RAY, ULTRASOUND, AND CONTRAST IMAGING | BRISTOL-MYERS SQUIBB PHARMA, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | LANTHEUS MEDICAL IMAGING, INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | VIP, ARGLU1, NGLY1 | ITGB3 1291/4885ITGAV 1016/4885ITGA2B 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.